- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06174805
위출구 폐쇄를 위한 AXIOS™ 위장조루술 IDE
절제 불가능한 악성 질환으로 인한 위출구 폐쇄에 대한 내강 부착 금속 스텐트를 이용한 내시경 초음파 유도 위장관루술에 대한 전향적 다기관, 단일 팔 연구
To investigate the safety and technical success of EUS-guided gastroenterostomy (EUS-GE) using the AXIOSTM lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm.
연구 개요
상세 설명
The study is a prospective multi-center, single -arm study with treatment of up to 67 subjects at up to 10 clinical centers. Subjects who meet all eligibility criteria will receive the AXIOS stent and up to 12 months follow-up.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Brigham and Women's Hospital
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, 미국, 10065
- New York Presbyterian/ Weill Cornell Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- University of Pittsburg Medical Center
-
-
Washington
-
Seattle, Washington, 미국, 98101
- Virginia Mason Medical Center
-
-
-
-
-
Leuven, 벨기에
- UZ Leuven
-
-
-
-
-
São Paulo, 브라질, 01246-092
- Instituto do Cancer do Estado de Sao Paulo
-
-
-
-
-
Hyderabad, 인도
- Asian Institute of Gastroenterology
-
-
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200433
- Shanghai Changhai Hospital
-
-
-
-
-
Montreal, 캐나다, H3Z 2E9
- McGill University Health Care
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Gastric outlet obstruction from unresectable malignant neoplasm
- Eligible for endoscopic intervention
- GOOS of 0 or 1 0 - no oral intake 1 - liquids only 2 - soft solids only 3 - low-residue or full diet
- 18 years of age or older
- Willing and able to comply with the study procedures or legally authorized representative (LAR) must provide written informed consent form (ICF) to participate in the study
- The distance between the gastric lumen and jejunal lumen must be no more than 1.0 cm
Exclusion Criteria:
- Patients with baseline ECOG > 2 and/or Karnofsky Performance score < 30
- Gastric cancer or any malignant infiltration precluding a cancer free puncture site of the AXIOSTM stent
- Abnormal coagulation INR > 1.5 and not correctable (per the discretion of the physician) or who require continuous complete anticoagulation, and/or any underlying condition associated with high risk of bleeding
- Altered anatomy of the upper gastrointestinal tract due to surgery of esophagus, stomach and duodenum that might preclude endoscopic gastroenterostomy
- Multiple-level bowel obstruction downstream from the intended location of the EUS-guided bypass confirmed by radiography such as small bowel series or computed tomography
- Presence of intraperitoneal fat between the gastric lumen and jejunal lumen estimated to be larger than 1.0 cm at the proposed site of AXIOSTM stent insertion
- Gastric varices located within a two-centimeter radius of the device insertion location on the gastric wall
- Ascites Grade ≥ 2 confirmed by cross-sectional imaging
- Vessels located within a two-centimeter radius of the device insertion location
- History of multiple abdominal surgeries and/or evidence of small bowel adhesions
- Allergic to any of the device materials
- Contraindications to use of electrical devices
- Pregnancy
- Prisoners and other vulnerable populations
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm |
Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Serious Adverse Events
기간: Through study completion, an average of 1 year
|
The proportion of subjects with one or more AXIOS stent related or AXIOS endoscopic and/or study procedure related serious adverse events through 30 days post stent placement. |
Through study completion, an average of 1 year
|
|
Technical Success
기간: During the procedure
|
The proportion of subjects that demonstrate technical Successful stent placement, defined as transmural placement of the AXIOS stent with confirmed stent patency by visualization of the contralateral wall of the small bowel through the AXIOS stent lumen. Visualization of blue dye in the gastric lumen or injection of contrast to confirm continuity of the gastroenteric lumen, may be used to provide supplemental confirmation of intended stent placement. Note: Visualization of blue dye in the gastric lumen or injection of contrast to confirm continuity of the gastroenteric lumen, may be used to provide supplemental confirmation of intended stent placement. |
During the procedure
|
|
Primary Effectiveness Endpoint
기간: through 14 days after procedure
|
Clinical Success defined as improvement of Gastric Outlet Obstruction Score (GOOS)by 1 point from baseline to any point during 14 days after AXIOS stent placement and GOOS remaining at 1 or more without the need for reintervention due to loss of stent function at 30 days post-index procedure or death, whichever comes first. |
through 14 days after procedure
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
스텐트 삽입 후 경구 섭취 재개 시간.
기간: 시술 직후
|
시술 직후
|
|
|
AXIOOSTM 스텐트 배치 후 화학요법을 시작하거나 재개하는 시간(해당되는 경우)
기간: 시술 직후
|
시술 직후
|
|
|
삶의 질 점수(SF-12 설문지)가 기준선에서 30일, 3개월, 6개월, 12개월로 변경되었습니다.
기간: 연구 수료를 통해 평균 1년
|
연구 수료를 통해 평균 1년
|
|
|
Clinical success over time defined as improvement of GOOS by 1 point from baseline at any time during 14 days after AXIOS stent placement and GOOS remaining at 1 or more. This endpoint will be evaluated at 3 months, 6 months, and 12 months
기간: Through study completion, an average of 1 year
|
A patient undergoing reintervention for GOO is considered a failure of clinical success |
Through study completion, an average of 1 year
|
|
Incidence of Device Deficiencies
기간: Immediately after the procedure
|
Including but not limited to stent migration/misplacement, stent occlusion, leakage at site of stent placement. |
Immediately after the procedure
|
|
Incidence of Reintervention for GOO
기간: Immediately after the procedure
|
defined as need for repeat treatment for persistent or recurrent GOO symptoms |
Immediately after the procedure
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Shayan Irani, MBBS, MD, Virginia Mason Medical Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .